ClinicalTrials.gg
RecruitingNCT06953986Updated Mar 6, 2026

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

An interventional study of Vonoprazan and Esomeprazole 40mg in GERD, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Asian Institute of Gastroenterology, India · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Planned enrollment
5th of 16
414 · median 118
Started
2025
with 3 others
No phase
5 of 16
3 open now
Registered
12th of 16
by date
Lead sponsor
2 of 16
Asian Institute of Gastroenterology, India

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 5th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 with no phase, and was the 12th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

Primary Objective

  • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.

Secondary Objectives

  • To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks.
  • To evaluate the incidence of adverse events across treatment groups.
Read the detailed description

Study Design:

  • This is a randomized, open-label, parallel-group, non-inferiority trial. Randomization and Blinding
  • Participants will be randomized in a 1:1:1 ratio to receive Vonaprazan 10 mg, Vonaprazan 20 mg, or Esomeprazole 40 mg once daily for 8 weeks.
  • Randomization will be stratified by baseline severity of esophagitis (LA grade B vs. C/D).
  • The study will be open-label, but the outcome assessors will be blinded. Study Arms

    1. Vonaprazan 10 mg once daily
    2. Vonaprazan 20 mg once daily
    3. Esomeprazole 40 mg once daily

      Duration:

  • 8 weeks of treatment, followed by endoscopic assessment and symptom evaluation.

I

Study Procedures:

Baseline :

  • Perform upper GI endoscopy to confirm LA grade B or higher esophagitis.
  • Record baseline GERD-Q score.
  • Randomize participants into one of the three treatment groups.
  • Dispense study medication. Follow-up (Week 4 - Interim Assessment)
  • Assess GERD-Q score.
  • Monitor adherence and adverse events. End-of-Treatment (Week 8 - Primary Outcome Assessment)
  • Repeat upper GI endoscopy to assess mucosal healing.
  • Reassess GERD-Q score.
  • Collect adverse event data.
  • Conclude study participation.
03

Conditions studied

  • GERD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age.
  • Endoscopically confirmed LA grade B, C, or D reflux esophagitis.
  • GERD symptoms (heartburn, regurgitation) for at least 4 weeks prior to enrollment.
  • Willing to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 weeks.
  • Prior esophageal surgery or radiation therapy.
  • Barrett's esophagus, esophageal stricture, or .
  • Pregnant or breastfeeding women.
  • History of PPI- GERD or severe gastroparesis.
  • Significant hepatic or renal impairment (/AST >3× , \<30 mL/min).
  • Use of NSAIDs, , or anticoagulants affecting healing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
414 participants (estimated)

Study arms

  • Other
    To determine whether Vonaprazon 10mg heals grade B esophagitis at 8 weeks

    Vonaprazon 10 mg heals gerd symptoms after 8 weeks

    Drug: Vonoprazan

  • Other
    To determine whether Vonaprazon 20mg heals grade B esophagitis at 8 weeks

    Vonaprazon 20 mg heals gerd symptoms after 8 weeks

    Drug: Vonoprazan

  • Other
    To determine whether esomeprazole 40mg heals grade B esophagitis at 8 weeks

    Esomeprazole 40mg heals gerd symptoms after 8 weeks

    Drug: Esomeprazole 40mg

Interventions

  • Vonaprazon is potassium competitive acid blockers

    Also known as: PCAB

  • DrugEsomeprazoleStudies of EsomeprazoleEsomeprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach

    Also known as: Proton pump inhibitor

06

What researchers measure

Primary outcomes

  1. • Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).

    healing of ulcers after taking vonaprazon 10mg, 20 mg

    Time frame: 8 weeks

  2. Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).

    healing of ulcers after taking esomeprazole 40mg

    Time frame: 8 weeks

Secondary outcomes

  1. • GERD-Q score improvement at 8 weeks (compared to baseline).

    symtoms improvement like heartburn, regurgitation which can be calculated with scale 1 (mild symptoms ) to 5 (worse symptoms)

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 11 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 1, 2025
StartActual
Dec 20, 2025
Primary completionEst.
Nov 20, 2026
CompletionEst.
Dec 12, 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06953986
Responsible party
Mohan Ramchandani (Director, Asian Institute of Gastroenterology, India) — Principal investigator
First posted
May 1, 2025
Start date
Dec 20, 2025
Primary completion
Nov 20, 2026 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Rajesh Goud Mr Maragoni, M.Pharm
Contact
rajeshgoud761@gmail.com
04023378888 ext. 410
Zaheer Dr Nabi, MD DNB
Contact
zaheernabi1978@gmail.com
04023378888 ext. 503
Mohan Dr Ramchandani, MD DM
study director · Asian Institute of Gastroenterology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonoprazan · Esomeprazole

Start the discussion